Applying a >0 % threshold (which is quite low in my mind), CD30 was expressed in approximately 12 % of the tumors from patients with Epstein-Barr virus (EBV) negative DLBCL, affecting younger people and showing a lower frequency of BCL2 expression and MYC/BCL2 co-expression. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.